{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002475","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.233942+00:00","generated_at":"2026-06-18T19:31:28.855302+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B","bullets":["Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.","Bio-Techne will pay $257M for a 20% ownership stake; close expected end of March 2023.","Remaining 80% can be acquired for $1B if Wilson Wolf hits $226M revenue or $136M EBITDA.","If milestone not met by Dec 31, 2027, Bio-Techne can buy for ~4.4x trailing revenue.","Wilson Wolf's G-Rex cell production tech is used by over 800 cell and gene therapy entities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002475","json":"https://secwatch.observer/filing/0001558370-23-002475.json","markdown":"https://secwatch.observer/filing/0001558370-23-002475.md","text":"https://secwatch.observer/filing/0001558370-23-002475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837023002475/0001558370-23-002475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837023002475/tmb-20230228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T19:31:28.855302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}